| Metric | Value ($ M) | vs Q2 FY26 |
|---|---|---|
| Revenue | 1.71 | 0.0% |
| Total Income | 1.71 | 0.0% |
| Expenditure | 10.93 | 3.7% |
| PBT | — | |
| Net Profit | -7.73 | 4.6% |
| OPM | — | |
| NPM | — | |
| EPS | -0.04 | 0.0% |
Rani Therapeutics Reports Q3 2026 Financial Results and Corporate Update
10 Nov 2026 · 3d ago, 3:36 am
Summary
Rani Therapeutics Holdings, Inc. reported financial results for the third quarter ended September 30, 2026, highlighting progress in its RaniPill® platform and corporate updates. The company secured acceptance into the FDA's Emerging Technology Program, which is expected to facilitate valuable engagement on technical and regulatory considerations. Contract revenue for the quarter was $1.7 million, a significant increase from zero in the prior year's period, driven by the Chugai collaboration. Despite a net loss of $8.8 million for the quarter, the company reported a strong cash position of $45.3 million, sufficient to fund operations through at least the end of 2027.
Key Highlights
- 1
Rani Therapeutics announced acceptance into the U.S. FDA’s Emerging Technology Program (ETP) in October 2026, enabling early FDA engagement for the RaniPill® platform technology.
- 2
Enrollment continues in the RT-114 Phase 1a expansion cohort, with data expected by the end of 2026.
- 3
Cash, cash equivalents, and marketable securities totaled $45.3 million as of September 30, 2026, with operations expected to be funded at least through the end of 2027.
- 4
Contract revenue for the three months ended September 30, 2026, was $1.7 million, compared to no contract revenue for the same period in 2025, primarily due to the collaboration and license agreement with Chugai.
- 5
Net loss for the three months ended September 30, 2026, was $8.8 million, compared to $7.9 million for the same period in 2025.
Management Comments
Talat Imran
The third quarter marked continued progress for the RaniPill® platform and, most recently, our acceptance into the FDA’s Emerging Technology Program in October provides an opportunity to engage with the Agency on technical, manufacturing and regulatory considerations related to the RaniPill® platform. We expect this engagement to be valuable as we continue to invest in manufacturing automation to support further clinical development. Combined with our rare disease, immunology, and obesity focused partnerships with Chugai, ProGen and PegBio, this milestone reflects our continued confidence in the RaniPill platform’s potential as an alternative to injectable biologics. With cash, cash equivalents and marketable securities of $45.3 million, we believe we are well positioned to fund operations at least through the end of 2027 and to execute on our priorities, including additional RT-114 data by year-end.
Informational and educational content only. Not investment advice.